ED Coding & Reimbursement Alert - 2006 Issue 19
PRESCRIPTION DRUGS: OIG To CMS--51 Drugs May Be Overpriced
Subscribe or sign in to view the full article.
Article Overview
This article reviews an HHS Office of Inspector General report on Medicare Part B drug pricing and CMS’s reaction to the report’s methodology and findings. It is relevant to readers tracking drug payment policy, ASP-based reimbursement, and federal oversight of Part B prescription drug pricing.
Why This Topic Matters
The article summarizes a policy issue that can affect Medicare Part B drug reimbursement levels and signals how CMS may respond to oversight findings. It matters to coding and reimbursement professionals who monitor drug payment changes, Medicare policy, and agency interpretation of pricing data.
What You Will Learn
- How Medicare Part B drug reimbursement is discussed in relation to average sales price methodology.
- What the OIG report examined regarding potentially overpriced drugs.
- How CMS responded to the OIG’s findings and calculations.
- The general significance of ASP-based payment oversight for Part B drugs.
Who Should Read This
- Medical coders
- Billing and reimbursement staff
- Compliance professionals
- Healthcare administrators
- Medicare policy analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com